BBI
$0.53
Brickell Biotech
$.01
1.25%
BBI
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.17)
Revenue:  $1.00 Mil
Wednesday
Nov 11
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when BBI reports earnings?
Beat
Meet
Miss

Where is BBI's stock price going from here?
Up
Flat
Down
Stock chart of BBI
Analysts
Summary of analysts' recommendations for BBI
Score
Grade
Pivots
Resistance
$0.57
$0.56
$0.54

$0.53

Support
$0.51
$0.50
$0.48
Tweet
Growth
Description
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company. It is focused on developing prescription therapeutics for treatment of skin diseases. The company's pipeline consists of therapeutics for hyperhidrosis, cutaneous T-cell lymphoma, psoriasis, and other prevalent severe skin diseases. Its products include Prozac(R), Gemzar(R), Cialis(R), Evista(R), Talz(R), Humulin(R), Cymbalta(R), Dysport(R), Juvederm(R) and Kybella(R). Brickell Biotech Inc., formerly known as Vical Incorporated, is based in San Diego, United States.